{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T22:01:38Z","timestamp":1770328898672,"version":"3.49.0"},"reference-count":49,"publisher":"MDPI AG","issue":"18","license":[{"start":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T00:00:00Z","timestamp":1758326400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Gansu Province Youth Science and Technology Fund program","award":["25JRRA1029"],"award-info":[{"award-number":["25JRRA1029"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Background: Acute myeloid leukemia (AML) remains a hematopoietic clonal malignancy that is characterized by a poor prognosis, largely attributable to chemotherapy resistance and a high incidence of post-chemotherapy relapse. Therefore, the identification of novel molecular markers is crucial for optimizing treatment regimens and improving outcomes for this disease. Methods: We first investigated the expression levels of poly(ADP-ribose)polymerase 3(PARP3) mRNA in data from our center and the Gene Expression Omnibus (GEO), then explored the role of PARP3 in AML through cell experiments. Results: Our results demonstrated that the expression levels of PARP3 were significantly elevated in AML samples compared to controls (p &lt; 0.05). Based on the median expression of PARP3, 151 cases of AML from TCGA data were divided into two groups. The results showed that PARP3-high group had markedly shorter overall survival (OS) than the PARP3-low group (OS: median: 1.18 vs. 3.88 years; p &lt; 0.001). The overexpression of PARP3 was correlated with older age and high-risk stratification in the AML from TCGA data (p &lt; 0.05). Finally, we confirmed that specifically down-regulating PARP3 expression impaired AML cell proliferation, disrupted cell cycle process, inhibited migration, accelerated apoptosis, and impaired the PI3K\/AKT\/mTOR signaling pathway in vitro. Conclusions: PARP3-mediated activation of the PI3K\/AKT\/mTOR signaling pathway enhances AML cell proliferation and migration, identifying it as a potential therapeutic target for poor-prognosis AML.<\/jats:p>","DOI":"10.3390\/cancers17183076","type":"journal-article","created":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T10:05:17Z","timestamp":1758535517000},"page":"3076","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["PARP3 Promotes AML Progression via Activation of PI3K\/AKT\/mTOR Signaling"],"prefix":"10.3390","volume":"17","author":[{"given":"Tingyong","family":"Cao","sequence":"first","affiliation":[{"name":"The First Clinical Medical College, Lanzhou University, Lanzhou 730000, China"},{"name":"Department of Hematology, The Second Hospital & Clinical Medical School, Lanzhou University, Lanzhou 730000, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yurong","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Hematology, The Second Hospital & Clinical Medical School, Lanzhou University, Lanzhou 730000, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huan","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Hematology, The Second Hospital & Clinical Medical School, Lanzhou University, Lanzhou 730000, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongbin","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Hematology, The Second Hospital & Clinical Medical School, Lanzhou University, Lanzhou 730000, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liangliang","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Hematology, The Second Hospital & Clinical Medical School, Lanzhou University, Lanzhou 730000, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoli","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Gansu Provincial Hospital, Lanzhou 730000, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"Zhao","sequence":"additional","affiliation":[{"name":"Gansu Provincial Clinical Medical Research Center for Molecular Diagnosis and Treatment of Hematological Diseases, The First Hospital, Lanzhou University, Lanzhou 730000, China"},{"name":"The Laboratory Center, The First Hospital, Lanzhou University, Lanzhou 730000, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2025,9,20]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1182\/blood.2022016867","article-title":"Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN","volume":"140","author":"Wei","year":"2022","journal-title":"Blood"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1111\/bjh.17746","article-title":"Updates on targeted therapies for acute myeloid leukaemia","volume":"196","author":"Kayser","year":"2022","journal-title":"Br. J. Haematol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1038\/nrm.2017.53","article-title":"The multifaceted roles of PARP1 in DNA repair and chromatin remodelling","volume":"18","author":"Nussenzweig","year":"2017","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.ccell.2019.07.007","article-title":"LMO2 Confers Synthetic Lethality to PARP Inhibition in DLBCL","volume":"36","author":"Parvin","year":"2019","journal-title":"Cancer Cell"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"216802","DOI":"10.1016\/j.canlet.2024.216802","article-title":"Targeting PARP14 with lomitapide suppresses drug resistance through the activation of DRP1-induced mitophagy in multiple myeloma","volume":"588","author":"Zhang","year":"2024","journal-title":"Cancer Lett."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s13045-022-01228-0","article-title":"Targeting PARP proteins in acute leukemia: DNA damage response inhibition and therapeutic strategies","volume":"15","author":"Padella","year":"2022","journal-title":"J. Hematol. Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"101283","DOI":"10.1016\/j.tranon.2021.101283","article-title":"PARP1 PARylates and stabilizes STAT5 in FLT3-ITD acute myeloid leukemia and other STAT5-activated cancers","volume":"15","author":"Dellomo","year":"2022","journal-title":"Transl. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"6757","DOI":"10.18632\/aging.204832","article-title":"PARP10 is highly expressed and associated with inferior outcomes in acute myeloid leukemia","volume":"15","author":"Wang","year":"2023","journal-title":"Aging"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"109094","DOI":"10.1016\/j.clim.2022.109094","article-title":"PARP14 promotes the growth and glycolysis of acute myeloid leukemia cells by regulating HIF-1\u03b1 expression","volume":"242","author":"Zhu","year":"2022","journal-title":"Clin. Immunol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1158\/1078-0432.CCR-17-2796","article-title":"IDH1\/2 Mutations Sensitize Acute Myeloid Leukemia to PARP Inhibition and This Is Reversed by IDH1\/2-Mutant Inhibitors","volume":"24","author":"Molenaar","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"3908","DOI":"10.18632\/oncotarget.23386","article-title":"Combination of a hypomethylating agent and inhibitors of PARP and HDAC traps PARP1 and DNMT1 to chromatin, acetylates DNA repair proteins, down-regulates NuRD and induces apoptosis in human leukemia and lymphoma cells","volume":"9","author":"Valdez","year":"2017","journal-title":"Oncotarget"},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Kohl, V., Flach, J., Naumann, N., Brendel, S., Kleiner, H., Weiss, C., Seifarth, W., Nowak, D., Hofmann, W.K., and Fabarius, A. (2019). Antileukemic Efficacy in Vitro of Talazoparib and APE1 Inhibitor III Combined with Decitabine in Myeloid Malignancies. Cancers, 11.","DOI":"10.3390\/cancers11101493"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1038\/s41419-024-07140-4","article-title":"Venetoclax triggers sublethal apoptotic signaling in venetoclax-resistant acute myeloid leukemia cells and induces vulnerability to PARP inhibition and azacitidine","volume":"15","author":"Tambe","year":"2024","journal-title":"Cell Death Dis."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1002\/jcb.21051","article-title":"PARP-3 associates with polycomb group bodies and with components of the DNA damage repair machinery","volume":"100","author":"Rouleau","year":"2007","journal-title":"J. Cell Biochem."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2783","DOI":"10.1073\/pnas.1016574108","article-title":"Poly(ADP-ribose) polymerase 3 (PARP3), a newcomer in cellular response to DNA damage and mitotic progression","volume":"108","author":"Boehler","year":"2011","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"15110","DOI":"10.1038\/ncomms15110","article-title":"PARP3 is a promoter of chromosomal rearrangements and limits G4 DNA","volume":"8","author":"Day","year":"2017","journal-title":"Nat. Commun."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.molcel.2010.12.006","article-title":"PARP-3 and APLF function together to accelerate nonhomologous end-joining","volume":"41","author":"Rulten","year":"2011","journal-title":"Mol Cell"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1080\/15384101.2019.1617454","article-title":"PARP3 comes to light as a prime target in cancer therapy","volume":"18","author":"Dantzer","year":"2019","journal-title":"Cell Cycle"},{"key":"ref_19","first-page":"5621","article-title":"Poly(ADP-ribose) polymerase-3 overexpression is associated with poor prognosis in patients with breast cancer following chemotherapy","volume":"16","author":"Song","year":"2018","journal-title":"Oncol. Lett."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"8617","DOI":"10.1007\/s13277-015-3554-4","article-title":"PARP3 interacts with FoxM1 to confer glioblastoma cell radioresistance","volume":"36","author":"Quan","year":"2015","journal-title":"Tumour Biol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/s10549-018-4888-6","article-title":"PARP3 inhibitors ME0328 and olaparib potentiate vinorelbine sensitization in breast cancer cell lines","volume":"172","author":"Amrein","year":"2018","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Nguekeu-Zebaze, L., Hanini, N., Noll, A., Wadier, N., Am\u00e9, J.C., Roegel, L., and Dantzer, F. (2022). PARP3 supervises G9a-mediated repression of adhesion and hypoxia-responsive genes in glioblastoma cells. Sci. Rep., 12.","DOI":"10.1038\/s41598-022-19525-6"},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Varol, A., Klauck, S.M., Dantzer, F., and Efferth, T. (2024). Enhancing cisplatin drug sensitivity through PARP3 inhibition: The influence on PDGF and G-coupled signal pathways in cancer. Chem. Biol. Interact., 398.","DOI":"10.1016\/j.cbi.2024.111094"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","article-title":"The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic\/Dendritic Neoplasms","volume":"36","author":"Khoury","year":"2022","journal-title":"Leukemia"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1182\/blood.2022015850","article-title":"International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: Integrating morphologic, clinical, and genomic data","volume":"140","author":"Arber","year":"2022","journal-title":"Blood"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"2383","DOI":"10.1038\/s41375-023-02054-0","article-title":"Expression profiling of extramedullary acute myeloid leukemia suggests involvement of epithelial-mesenchymal transition pathways","volume":"37","author":"Ottone","year":"2023","journal-title":"Leukemia"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1182\/blood.2019002548","article-title":"The EMT modulator SNAI1 contributes to AML pathogenesis via its interaction with LSD1","volume":"136","author":"Carmichael","year":"2020","journal-title":"Blood"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"3287","DOI":"10.1111\/cas.15855","article-title":"Acute myeloid leukemia (AML)-derived mesenchymal stem cells induce chemoresistance and epithelial-mesenchymal transition-like program in AML through IL-6\/JAK2\/STAT3 signaling","volume":"114","author":"Lu","year":"2023","journal-title":"Cancer Sci."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1038\/leu.2014.305","article-title":"Dual PI3K\/mTOR inhibition shows antileukemic activity in MLL-rearranged acute myeloid leukemia","volume":"29","author":"Metzeler","year":"2015","journal-title":"Leukemia"},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Nepstad, I., Hatfield, K.J., Gr\u00f8nnings\u00e6ter, I.S., and Reikvam, H. (2020). The PI3K-Akt-mTOR Signaling Pathway in Human Acute Myeloid Leukemia (AML) Cells. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21082907"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1002\/ajh.27584","article-title":"Treatment of Relapsed\/Refractory AML-Novel Treatment Options Including Immunotherapy","volume":"100","author":"Moore","year":"2025","journal-title":"Am. J. Hematol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1038\/s41573-020-0076-6","article-title":"Poly(ADP-ribose) polymerase inhibition: Past, present and future","volume":"19","author":"Curtin","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"e17","DOI":"10.1017\/erm.2024.13","article-title":"PARP enzymes and mono-ADP-ribosylation: Advancing the connection from interferon-signalling to cancer biology","volume":"26","author":"Morone","year":"2024","journal-title":"Expert Rev. Mol. Med."},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Ukraintsev, A., Kutuzov, M., Belousova, E., Joyeau, M., Golyshev, V., Lomzov, A., and Lavrik, O. (2023). PARP3 Affects Nucleosome Compaction Regulation. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24109042"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"10076","DOI":"10.1073\/pnas.1801591115","article-title":"PARP3 promotes long-range end joining in murine cells","volume":"115","author":"Layer","year":"2018","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"64109","DOI":"10.18632\/oncotarget.11627","article-title":"PARP3 controls TGF\u03b2 and ROS driven epithelial-to-mesenchymal transition and stemness by stimulating a TG2-Snail-E-cadherin axis","volume":"7","author":"Karicheva","year":"2016","journal-title":"Oncotarget"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"12404","DOI":"10.1038\/ncomms12404","article-title":"PARP3 is a sensor of nicked nucleosomes and monoribosylates histone H2B(Glu2)","volume":"7","author":"Grundy","year":"2016","journal-title":"Nat. Commun."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.molcel.2016.09.023","article-title":"Nick Your DNA, Mark Your Chromatin","volume":"64","author":"Nardozza","year":"2016","journal-title":"Mol. Cell."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/s13045-022-01267-7","article-title":"Molecular profiling and clinical implications of patients with acute myeloid leukemia and extramedullary manifestations","volume":"15","author":"Eckardt","year":"2022","journal-title":"J. Hematol. Oncol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"e16","DOI":"10.1017\/erm.2023.13","article-title":"Targeting N-cadherin (CDH2) and the malignant bone marrow microenvironment in acute leukaemia","volume":"25","author":"Parker","year":"2023","journal-title":"Expert. Rev. Mol. Med."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1186\/s12967-018-1539-y","article-title":"Upregulation of the EMT marker vimentin is associated with poor clinical outcome in acute myeloid leukemia","volume":"16","author":"Wu","year":"2018","journal-title":"J. Transl. Med."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1038\/nrd1902","article-title":"Exploiting the PI3K\/AKT pathway for cancer drug discovery","volume":"4","author":"Hennessy","year":"2005","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1186\/s12943-023-01827-6","article-title":"PI3K\/AKT\/mTOR signaling transduction pathway and targeted therapies in cancer","volume":"22","author":"Glaviano","year":"2023","journal-title":"Mol. Cancer"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.semcancer.2021.06.019","article-title":"Attacking the PI3K\/Akt\/mTOR signaling pathway for targeted therapeutic treatment in human cancer","volume":"85","author":"Yu","year":"2022","journal-title":"Semin Cancer Biol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1038\/s41418-018-0233-1","article-title":"PARP3, a new therapeutic target to alter Rictor\/mTORC2 signaling and tumor progression in BRCA1-associated cancers","volume":"26","author":"Beck","year":"2019","journal-title":"Cell Death Differ."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1038\/s41419-020-03167-5","article-title":"PARP3 promotes astrocytic differentiation through a tight regulation of Nox4-induced ROS and mTorc2 activation","volume":"11","author":"Wang","year":"2020","journal-title":"Cell Death Dis."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1182\/blood-2004-08-3225","article-title":"Essential role for the p110delta isoform in phosphoinositide 3-kinase activation and cell proliferation in acute myeloid leukemia","volume":"106","author":"Sujobert","year":"2005","journal-title":"Blood"},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Darici, S., Alkhaldi, H., Horne, G., J\u00f8rgensen, H.G., Marmiroli, S., and Huang, X. (2020). Targeting PI3K\/Akt\/mTOR in AML: Rationale and Clinical Evidence. J. Clin. Med., 9.","DOI":"10.3390\/jcm9092934"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1007\/s00018-015-1867-5","article-title":"Targeting PI3K\/AKT\/mTOR network for treatment of leukemia","volume":"72","author":"Bertacchini","year":"2015","journal-title":"Cell Mol. Life Sci."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/17\/18\/3076\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T18:46:20Z","timestamp":1760035580000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/17\/18\/3076"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,20]]},"references-count":49,"journal-issue":{"issue":"18","published-online":{"date-parts":[[2025,9]]}},"alternative-id":["cancers17183076"],"URL":"https:\/\/doi.org\/10.3390\/cancers17183076","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,20]]}}}